Effect of Fasting on the Size of Abdominal Lymphatic Tumors in Women
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00552955|
Recruitment Status : Completed
First Posted : November 2, 2007
Last Update Posted : February 14, 2018
This study will examine the effect of fasting on lymphangioleiomyomas abdominal tumors formed from enlarged lymph nodes containing lymphatic fluid. Previous studies have determined that these tumors increase in size in the evening, but this result could stem from the fact that previous study participants were tested after eating lunch. The purpose of the study is to help researchers understand the factors that produce changes in size of lymphangioleiomyomas, as well as to improve the ability of medical professionals to diagnose lymphangioleiomyomas and avoid confusing these tumors with other malignant tumors.
Volunteers must be women who are at least 18 years of age and who have been diagnosed with lymphangioleiomyomas in the abdominal or pelvic areas. Candidates who have had lung or kidney transplants or who have type 1 diabetes will be excluded. Candidates will be screened with a physical examination and medical history.
During the study, participants will be admitted to a National Institutes of Health clinical center for three days to undergo a number of tests. Tests will include routine blood and urine tests, and electrocardiogram, research blood testing, and abdominal and pelvic ultrasounds....
|Condition or disease|
|Lymphangioleiomyomas Tuberous Sclerosis Lymphangioleiomyomatosis|
|Study Type :||Observational|
|Actual Enrollment :||35 participants|
|Official Title:||Effect of Fasting on the Size of Lymphangioleiomyomas in Patients With Lymphangioleiomyomatosis|
|Study Start Date :||October 26, 2007|
|Estimated Study Completion Date :||March 21, 2016|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00552955
|United States, Maryland|
|National Institutes of Health Clinical Center, 9000 Rockville Pike|
|Bethesda, Maryland, United States, 20892|
|Principal Investigator:||Angelo M Taveira-DaSilva, M.D.||National Heart, Lung, and Blood Institute (NHLBI)|